Although the prostate specific antigen (PSA) has been widely used for early diagnosis and monitoring the recurrence of prostate cancer [8,9,10], PSA levels are not always consistent with the grades of cancers, the status of cancer progress, and cancer metastasis; additionally, PSA is not a therapeutic target. This evidence concerns the gene KLK3 and prostate carcinoma.